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Primary Macrophage Chemotaxis 
Induced by Cannabinoid Receptor 
2 Agonists Occurs Independently 
of the CB2 Receptor
Lewis Taylor1, Ivy Christou1, Theodore S. Kapellos1, Alice Buchan1, 
Maximillian H. Brodermann1, Matteo Gianella-Borradori2, Angela Russell2, Asif J. Iqbal1 & 
David R. Greaves1
Activation of CB2 has been demonstrated to induce directed immune cell migration. However, the 
ability of CB2  to act as a chemoattractant receptor in macrophages remains largely unexplored. 
Using a real-time chemotaxis assay and a panel of chemically diverse and widely used CB2 agonists, 
we set out to examine whether CB2 modulates primary murine macrophage chemotaxis. We report 
that of 12 agonists tested, only JWH133, HU308, L-759,656 and L-759,633 acted as macrophage 
chemoattractants. Surprisingly, neither pharmacological inhibition nor genetic ablation of CB2 had 
any effect on CB2 agonist-induced macrophage chemotaxis. As chemotaxis was pertussis toxin 
sensitive in both WT and CB2-/- macrophages, we concluded that a non-CB1/CB2, Gi/o-coupled GPCR 
must be responsible for CB2 agonist-induced macrophage migration. The obvious candidate receptors 
GPR18 and GPR55 could not mediate JWH133 or HU308-induced cytoskeletal rearrangement or 
JWH133-induced β -arrestin recruitment in cells transfected with either receptor, demonstrating that 
neither are the unidentified GPCR. Taken together our results conclusively demonstrate that CB2 is 
not a chemoattractant receptor for murine macrophages. Furthermore we show for the first time 
that JWH133, HU308, L-759,656 and L-759,633 have off-target effects of functional consequence 
in primary cells and we believe that our findings have wide ranging implications for the entire 
cannabinoid field.
The cannabinoid receptors, CB1 and CB2, received their name from the discovery that they are acti-
vated by Δ 9-tetrahydrocannabinol (THC), the major psychoactive component of cannabis1. These G 
protein-coupled receptors (and potentially other putative GPCRs2), in combination with their endoge-
nous ligands (the endocannabinoids) and the enzymes that synthesise and degrade these cognate lipids, 
comprise the endocannabinoid system3. Both CB1 and CB2 are Gi/o-coupled, therefore their activation 
results in adenylyl cyclase inhibition and decreased intracellular cAMP4. Moreover, both receptors can 
initiate additional downstream signalling events, including activation of intracellular kinases and voltage 
gated Ca2+ channels5,6. Whilst CB1 is predominantly expressed throughout the brain7, CB2 is primarily 
localised on cells of the immune system8.
This expression profile led to the hypothesis that CB2 acts as an immunomodulatory receptor. Indeed, 
CB2 has been shown to modulate multiple inflammatory diseases and immune cell functions9–11, includ-
ing directed migration or chemotaxis12. Activation of CB2 has been demonstrated to elicit leukocyte 
chemotaxis as the synthetic and highly potent CB2 agonists JWH015 and JWH133 cause human mono-
cyte migration13 and the endocannabinoid 2-arachidonylglycerol (2-AG) induces the directed migration 
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of B lymphocytes14, natural killer cells15, eosinophils16, the myeloid HL-60 cell line and human mono-
cytes17. In all cases SR144528 (a CB2 inverse agonist) inhibited 2-AG-induced chemotaxis, demonstrating 
dependence on CB2 signalling.
However, it is becoming increasingly apparent that CB2 plays a complex role in the modulation of leu-
kocyte chemotaxis. Although 2-AG acts as a chemoattractant, the mixed CB1/CB2 agonists WIN,55212-2 
and CP55,940 fail to elicit directed cellular migration14,17, hinting that functional selectivity may impact 
CB2-mediated chemotaxis. This phenomenon, also known as biased agonism, is defined as the ability 
of different ligands at the same receptor to activate distinct downstream signalling pathways18 and has 
already been documented for ligands acting at CB219,20. However as previous chemotaxis studies only use 
a limited range of CB2 agonists, the extent and importance of functional selectivity within CB2-mediated 
chemotaxis is unknown. Furthermore, whether CB2 acts as a chemoattractant receptor in macrophages 
remains largely unexplored. As these innate immune cells play a core role within the induction and 
continuation of an inflammatory response, they are central to many chronic inflammatory diseases21,22. 
Therefore understanding the mechanisms that regulate macrophage dynamics and migration are of great 
interest.
Previous work has demonstrated that the activation of CB2 may negatively regulate macrophage migration 
to other chemotactic factors. CP55,940, alongside the phytocannabinoid cannabidiol, inhibits the migra-
tion of rat macrophages towards the chemoattractant peptide N-formyl-methionyl-leucyl-phenylalanine 
(fMLP)23,24. Furthermore, Steffens et al. demonstrated that Δ 9-THC treatment of murine macrophages 
inhibits their chemotaxis towards CCL225, whilst a parallel report by Raborn et al. found that Δ 9-THC 
and CP55,940 also inhibit macrophage migration towards CCL526. However, this negative role seems to 
be at odds with CB2 behaving as a chemoattractant receptor in other leukocyte populations and further 
complexity is added by the finding that, in contrast to 2-AG, JWH015, CP55,940 and Δ 9-THC are unable 
to inhibit neutrophil chemotaxis toward fMLP27,28, suggesting that functional selectivity may also impact 
this process as well.
With this in mind, we aimed to use a panel of commercially available and chemically diverse CB2 
agonists to elucidate whether CB2 is a chemoattractant receptor in primary murine macrophages and 
assess the contribution of functional selectivity. We found that of twelve CB2 agonists tested, only 
JWH133, HU308, L-759,656 and L-759,633 induced macrophage cytoskeletal rearrangement and chem-
otaxis. Although chemotaxis was pertussis toxin sensitive, genetic ablation of CB2 had no effect on CB2 
agonist-induced macrophage signalling or chemotaxis. Therefore, we conclude that CB2 is not a che-
moattractant receptor in murine macrophages, and that chemotaxis elicited by CB2 agonists occurs via 
an off-target effect at a non-CB1/CB2 Gi/o-coupled GPCR.
Materials and Methods
Reagents. Cannabinoids and cannabinoid receptor inverse agonists were purchased from Tocris 
(Bristol, UK). Murine CCL5 was purchased from Peprotech (London, UK). Murine chemerin and 
murine CCL2 were obtained from R & D systems (Abingdon, UK). Pertussis toxin (PTX) was pur-
chased from Merck Millipore (Feltham, UK). Bio-gel polyacrylamide beads (P-100 fine 45-90 μ m) were 
purchased from Biorad (Hertfordshire, UK). cOmplete, EDTA free protease inhibitor cocktail tablets 
were purchased from Roche (Burgess Hill, UK). Rabbit anti-phospho-ERK1/2 and total ERK1/2 were 
purchased from Cell Signalling Technologies (Danvers, MA, USA). HRP-conjugated Goat anti-rabbit 
secondary was purchased from Biorad. CIM-16 plates were purchased from Cambridge bioscience 
(Cambridge, UK). All cell culture media were obtained from PAA systems (Yeovil, UK). Phosphatase 
inhibitor cocktail 2 and all other laboratory chemicals were purchased from Sigma Aldrich (Dorset, UK). 
DIAS2 (3-((2’-cyanobenzyl)thio)-5H-[1,2,4]triazino[5,6b]indole) was synthesized by Dr. Angela Russell 
(University of Oxford, UK)
Animals. C57BL6/J mice were obtained from Harlan Laboratories (Oxfordshire, UK). Cannabinoid 
receptor 2 knockout mice (herein referred to as CB2-/- mice) were purchased from the Jackson 
Laboratories (Bar harbour, ME, USA). These mice were originally produced by Deltagen (San Mateo, 
CA, USA) and have been backcrossed at least 5 generations onto the C57BL6/J background. All animal 
studies were conducted with ethical approval from the Dunn School of Pathology Local Ethical Review 
Committee and in accordance with the UK Home Office regulations (Guidance on the Operation of 
Animals, Scientific Procedures Act, 1986)
Generation of N-terminal tagged GPCR constructs. All tagged GPCR constructs were pur-
chased from Life Technologies, using their GeneArt® Gene Synthesis service. Briefly, the protein cod-
ing regions for murine C5aR1 (Transcript variant 1, NM_007577.4), CB2 (NM_009924.3), GPR55 
(NM_001033290.2), and GPR18 (NM_182806.1) were modified by the removal of the endogenous start 
codon and the addition of an N-terminal EcoRI restriction site, a Kozak consensus sequence, an epitope 
tag (C5aR1 and GPR18 – hemagglutinin (HA); CB2 – FLAG; GPR55 – c-myc) and a C-terminal NotI 
restriction site. The sequences were cloned into pcDNA3.1(+ ) and all constructs 100% sequence verified. 
Vectors were propagated by transformation into DH5α chemically competent cells (Life Technologies) 
following the manufacturers protocol. After being spread on LB agar plates containing 50 μ g/ml ampi-
cillin and incubated overnight at 37 °C, single colonies were placed into 7 ml of LB medium containing 
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50 μ g/ml ampicillin and incubated for 10 hours at 37 °C with constant shaking (300 rpm). Next 150 μ l of 
this culture was added to 150 ml LB medium containing 50 μ g/ml ampicillin and incubated for 20 hours 
at 37 °C with constant shaking (300 rpm). The cells were then pelleted and plasmid DNA extracted using 
the Qiagen HiSpeed plasmid midi kit following the manufacturer’s instructions. DNA concentration and 
purity was determined using a NanoDrop™ ND-1000 spectrophotometer (Thermo Scientific).
Bio-gel and thioglycollate elicitation of peritoneal exudate cells (PECs). Male C57BL/6J mice 
or male and female CB2-/- mice were injected intraperitoneally with either 1 ml of sterile 2% bio-gel pol-
yacrylamide beads (P100 fine, 45-90 μ M) suspended in phosphate buffered saline (PBS) or 1 ml of 4% 
thioglycollate (brewer thioglycollate media, Sigma-Aldrich). After four days, mice were sacrificed and the 
elicited cells collected by peritoneal lavage with 10 ml ice cold PBS containing 2 mM EDTA.
PEC macrophage enrichment. Following peritoneal lavage bio-gel elicited PECs were pelleted by 
centrifugation at 200 × g for 5 min at 4 °C and then re-suspended in 10 ml chemotaxis buffer (RPMI 1640 
supplemented with 0.5% BSA and 25 mM HEPES) before being transferred into 10 cm petri dishes (one 
per mouse; non-tissue culture treated) and left for 2 hours at 37 °C, 5% CO2. After three washes with 
10 ml PBS to remove any non-adherent cells, the medium was replaced with 10 ml chemotaxis buffer 
and dishes left overnight at 37 °C, 5% CO2. Adherent macrophages were collected by the addition of 
PBS, containing 10 mM EDTA, and gentle agitation. Macrophages were then pelleted by centrifugation 
at 200 × g for 5 min at 4 °C, resuspended in chemotaxis buffer, counted and then adjusted to the desired 
cell concentration. Macrophage purity was determined by flow cytometry as described below.
Modified Boyden chamber chemotaxis. Following peritoneal lavage, bio-gel elicited PECs were pel-
leted by centrifugation at 200 × g for 5 min at 4 °C and then re-suspended at a cell density of 5 × 106 cells/
ml in chemotaxis buffer pre-warmed to 37 °C. Cannabinoid or vehicle (325 μ l - 0.3% DMSO in chemot-
axis buffer) was added to the lower chamber of a 96-well Neuroprobe ChemoTx plate (8 μ m pore size – 
Receptor technologies, Leamington Spa, UK). Following attachment to the plate, 80 μ l of cell suspension 
(4 × 105 cells) was added onto the filter site above each well. The plate was then incubated for 4 hours at 
37 °C, 5% CO2. The assay was terminated by detaching the filter and wiping to remove non-migrated cells 
from the filter top. Migrated cells were then fixed with 1% formalin in PBS for 10 min, rinsed with PBS 
and then DAPI-stained (1 μ g/ml in distilled water) for 10 min in the dark. Following a final rinse with 
PBS, the filter sites were cut, mounted using fluorescent mounting medium, and then left overnight at 
4 °C. The following day, DAPI-stained nuclei were detected using an Axiovert 200 inverted fluorescence 
microscope (Zeiss, Cambridge, UK) and two images taken per filter site. Metamorph software (Molecular 
Devices, Wokingham, UK) was used to count the number of nuclei in each image. Migration index (MI) 
was calculated by dividing the number of migrated cells for each treatment by the mean of the number 
of cells migrated towards vehicle alone.
ACEA xCELLigence chemotaxis assay. Real-time chemotaxis analysis was conducted as previously 
described29. Briefly, vehicle (0.3% DMSO in chemotaxis buffer), cannabinoid, chemerin or chemokine 
(160 μ l) at the desired final concentration was added to the lower chamber of a CIM-16 plate. The upper 
chamber was subsequently attached and 50 μ l of pre-warmed chemotaxis buffer added to each of the 
upper chambers. Following equilibration at RT for 30 min, the plate was transferred into the RTCA-DP 
system for background analysis. Bio-gel elicited PECs (50 μ l - 4 × 105 cells/well), enriched macrophages, 
thioglycollate elicited macrophages or bone marrow neutrophils (50 μ l - 2 × 105 cells/well) in chemotaxis 
buffer were then added to all upper wells and plate replaced into the RTCA-DP system. Cell Index (CI) 
measurements were then taken every 5 seconds over the 3-4 hour assay period. Migration Index (MI) was 
calculated as maximum cell index minus minimum cell index and pooled data are displayed as a fold 
change relative to cells migrating towards vehicle alone.
ACEA 96 well ECIS assay. Following peritoneal lavage, bio-gel elicited PECs were pelleted by cen-
trifugation at 200 × g for 5 min at 4 °C and then re-suspended at a cell density of 1 × 106 cells/ml in 
chemotaxis buffer pre-warmed to 37 °C. Chemotaxis buffer (50 μ l) was then added into all wells of a 96 
well E-plate and a background measurement taken. Afterwards, 50 μ l of cell suspension was added to all 
wells (50,000 cells/well) and cells were then left at 37 °C, 5% CO2 for 2-3 hours to adhere until the CI had 
reached a stable plateau. Cells were then stimulated with either vehicle (0.3% DMSO) or cannabinoid at 
the indicated concentration and CI measurements taken every 5 seconds for 1-2 hours after agonist addi-
tion. Data are displayed as change in CI from the point of agonist addition (Δ Cell Index) and response 
was calculated as maximum CI – CI at point of agonist addition (Δ Cell Index (max-min)). For the 
receptor transfection studies, transfected CHO cells were plated into a 96 well E-plate (50 μ l; 25,000 cells/
well) in Ham’s F12 with 2% FCS and left overnight at 37 °C, 5% CO2 to reach a stable baseline and allow 
tagged GPCR expression. After stimulation with ligand (Cannabinoid 10 μ M, C5a 10 nM or vehicle (0.3% 
DMSO)), CI measurements were taken every 5 seconds for 1-2 hours after agonist addition. Response 
was calculated as: CI immediately before agonist addition – CI at the time point corresponding to C5a 
peak in C5aR1 transfected cells.
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Intracellular cAMP measurement. Intracellular cAMP levels were measured using Discoverx 
cAMP Hunter™ eXpress kits (Discoverx, Birmingham, UK) following the manufacturer’s protocol. Briefly, 
CHO-K1 cells overexpressing the human CB2 receptor were plated into a ½ area 96 well plate (15,000 cells/
well) and incubated at 37 °C, 5% CO2 for 24 hours. The media was then removed and replaced with 
22.5 μ l of assay buffer containing a cAMP capture antibody. Cells were then stimulated for 30 min at 
37 °C, 5% CO2 with either vehicle (4.8% DMSO with 80 μ M forskolin) or cannabinoid at 4x the final 
desired concentration (Final concentrations were 1.2% DMSO and 20 μ M forskolin). Following stimu-
lation, cell lysis and cAMP detection were performed as per the manufacturer’s protocol. Luminescence 
measurements were taken using a PHERAstar microplate reader (BMG Labtech, Aylesbury, UK).
Cannabinoid stimulation of bio-gel elicited murine macrophages. Following peritoneal lavage, 
bio-gel elicited PECs were pelleted by centrifugation at 200 xg for 5 min at 4 °C and then re-suspended at 
a cell density of 1 × 106 cells/ml in chemotaxis buffer pre-warmed to 37 °C. PECs (2 × 106 cells/well) were 
then seeded in 6 well plates and allowed to adhere for 2 hours at 37 °C, 5% CO2. After three washes with 
pre-warmed PBS to remove non-adherent cells and enrich for macrophages, 2 ml of chemotaxis buffer 
was added to each well and the plates left for 1 hour at 37 °C, 5% CO2. The media was then replaced 
with 1 ml warmed chemotaxis buffer and left for a further hour at 37 °C, 5% CO2, after which 200 μ l 
of vehicle (1.8% DMSO in chemotaxis buffer) or 60 μ M cannabinoid was added to the corresponding 
wells (yielding a final concentration of 10 μ M at 0.3% DMSO). Plates were then incubated for 30 min 
at 37 °C, 5% CO2. For SR144528 studies, 100 μ l of either vehicle (3.3% DMSO) or 11 μ M SR144528 was 
added to the corresponding wells and plates incubated for 30 min at 37 °C, 5% CO2 (yielding a final 
concentration of 1 μ M SR144528 at 0.3% DMSO). Following antagonist pre-treatment, wells received 
100 μ l of either vehicle (3.9% DMSO in chemotaxis buffer) or 120 μ M cannabinoid (yielding final con-
centrations of 10 μ M cannabinoid and 0.6% DMSO) and plates incubated for 30 min at 37 °C, 5% CO2. 
After stimulation, the media was rapidly removed and the plates placed at − 80 °C. Cell lysates were 
prepared by the addition to each well of 180 μ l cell lysis buffer (150 mM NaCl, 0.8 mM MgCl2, 5 mM 
EGTA, 50 mM HEPES, 1% IGEPAL CA-630) supplemented with protease and phosphatase inhibitors. 
Cells were then manually disrupted and supernatant centrifuged at 16,000 × g for 10 min at 4 °C. Protein 
concentration of cell debris free supernatant was determined using a BCA protein assay kit (Thermo 
Fisher scientific, Loughborough, UK) following the manufacturer’s protocol. Samples were then diluted 
3:1 with 4x laemmli buffer (250 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.004% bromophenol blue, 
20% β -mercaptoethanol), heated at 95 °C for 5 min and either loaded directly onto an SDS-PAGE gel or 
placed at − 80 °C.
Phosphorylated and total ERK1/2 western blotting. Samples (30 μ g total protein) were sep-
arated using a 10% SDS-PAGE gel and transferred onto Hybond ECL nitrocellulose (GE healthcare, 
Buckinghamshire, UK). Membranes were blocked with 5% BSA in TBS-T for 2 hours at RT or over-
night at 4 °C. After blocking, membranes were incubated with rabbit anti-phospho-ERK1/2 (1:2000) 
diluted in 5% BSA/TBS-T for 2 hours at RT or overnight at 4 °C. Membranes were then incubated with a 
HRP-conjugated anti-rabbit secondary antibody (1:20,000) for 1 hour at RT. Protein bands were visualised 
by incubating the membranes for 5 min with Amersham™ ECL prime and subsequent exposure to x-ray 
film over a range of exposure times. To confirm equal protein loading between samples, bound antibod-
ies were removed by incubating the nitrocellulose membranes in stripping buffer (60 mM Tris-HCl pH 
6.8, 2% SDS, 0.8% β -mercaptoethanol) for 30 min at 50 °C. Membranes were then blocked with 5% BSA 
in TBS-T for 2 hours at RT and then incubated with rabbit anti-ERK1/2 (1:2000) diluted in 5% BSA/
TBS-T for 2 hours. Protein band detection was conducted as described above. Densitometric analysis 
was conducted using Image Studio Lite (LI-COR Biosciences, Cambridge, UK) with data displayed as 
fold change compared to vehicle of phospho-ERK1/2 band density divided by total ERK1/2 band density.
Flow cytometry. Cells (5 × 105) were placed into polypropylene tubes and pelleted by centrifugation at 
200 × g for 5 mins at 4 °C. These were then resuspended in FACS buffer (PBS containing 2% FCS, 25 mM 
HEPES and 5 mM EDTA) supplemented with mouse IgG and mouse SeroBlock FcR® (AbD Serotec, 
Oxford, UK) and left on ice for 30 min. For studies using CHO cells, the cell pellet was resuspended in 
FACS buffer alone. Specific staining was conducted using the following antibodies and appropriate iso-
type controls: F4/80 (1:100, FITC, clone CI:A3-1, Abcam, Cambridge, UK), Ly-6B.2 (1:100, Alexa Fluor® 
647, clone 7/4, Abd Serotec), Ly-6G (1:100, PE, clone 1A8, BD Biosciences, Oxford, UK), CD11b (1:100, 
FITC, clone M1/70, BD Biosciences) anti-HA (1:50, APC, clone GG8-1F3.3.1, Miltenyi Biotec, Surrey, 
UK), anti-c-myc (1:10, FITC, clone SH1-26E7.1.3, Miltenyi Biotec), anti-FLAG (anti-DYKDDDDK, 1:50, 
PE, clone L5, Biolegend, London, UK) for 1 hour on ice. Cells were then pelleted by centrifugation at 
200 × g for 5 mins at 4 °C, resuspended in 1% formaldehyde and analysed using a Dako Cyan ADP flow 
cytometer (Beckman Coulter Ltd, High Wycombe, UK) and FlowJo software (V10, Tree Star, Ashland, 
USA).
RNA extraction and reverse transcription. RNA extraction of enriched bio-gel macrophages 
was conducted using the RNeasy® Mini Kit (Qiagen, Manchester, UK) following the manufacturer’s 
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instructions. RNA concentration and quality was determined using a NanoDrop™ ND-1000 spectropho-
tometer. cDNA was produced from the purified RNA using the QuantiTect® Reverse Transcription kit 
(Qiagen) following the manufacturer’s protocol.
Real-time PCR. Expression of actin, CB2, GPR55 and GPR18 in enriched bio-gel macrophages 
was determined using the following primers (5’> 3’): Actin Fwd CCAACAGCAGACTTCCAGGATT, 
Actin Rev CTGGCAAGAAGGAGTGGTAACTG, CB2 Fwd GGTCCTCTCAGCATTGATTTC, 
CB2 Rev GCCCAGTAGGTAGTCGTTAG, GPR55 Fwd AACCTTCATCGGCTCCTCT, GPR55 
Rev ATTCTTCCTGTCCCACTCCT, GPR18 Fwd CGACCAAGAAAAGAACCACAG, GPR18 Rev 
AATGAAAGCAAGAAGCCACA and SYBR Select PCR master mix (Life Technologies). 500 ng of cDNA 
was used per reaction with the following thermal profile: 95 °C for 5 min, 40 cycles of 95 °C for 30 s, 
60 °C for 20 s, 72 °C for 30 s and a final step of 72 °C for 5 min using a RG-3000 thermal cycler (Corbett 
research, Manchester UK). Analysis was conducted using Rotor-gene 6 software.
CHO cell GPCR transfections. CHO cells were cultured in Ham’s F12 medium containing 2% FCS 
until 80-90% confluent. After washing twice with 15 ml PBS, cells were detached by incubation with 
TrypLE™ Express (5 ml - T75 flask, 10 ml - T175 flask, Life technologies, Paisley, UK) for 3 min at 37 °C, 
5% CO2. After being collected into 25 ml Ham’s F12 with 2% FCS and pelleted by centrifugation at 
200 × g at 4 °C, cells were resuspended in Ham’s F12 with 2% FCS, counted and cell density adjusted to 
1 × 106 cells/ml. For receptor transfections, the Amaxa® cell line nucleofector® kit T was used following 
the manufacturers recommended protocol for CHO cells. Briefly, 1 × 106 cells were pelleted by centrifu-
gation at 200 × g for 10 min at RT and then resuspended in 100 μ l nucleofector® solution T. After addition 
of Plasmid DNA (2 μ g - either tagged GPCR or empty vector) the suspension was transferred into a 
provided cuvette, placed into the nucleofector® device and transfected using program U-023. Cells were 
then made to a final volume of 2 ml using Ham’s F12 with 2% FCS and plated into a 96 well E-plate (see 
above protocol for details). The remaining cells were added into a 6 well dish containing 2 ml Ham’s F12 
with 2% FCS and left overnight at 37 °C, 5% CO2 for flow cytometric analysis of transfection efficiency. 
Cells were detached by incubation with 500 μ l TrypLE™ Express per well for 3 min at 37 °C, 5% CO2. 
After collection into 5 ml Ham’s F12 with 2% FCS, cells were pelleted, counted and then used for flow 
cytometry as detailed above.
Discoverx GPCR β-arrestin recruitment screening. Recruitment of β -Arrestin to 241 human 
GPCRs after stimulation with 10 μ M JWH133 was measured using the Discoverx PathHunter® eXpress 
β -Arrestin GPCR Assay following the manufacturer’s protocol. Briefly, cells were seeded into white 
walled, 384 well microplates and incubated at 37 °C for the appropriate time period prior to testing. 
JWH133 or vehicle (1% DMSO) was then added to the corresponding wells and the plate incubated 
at either RT or 37 °C for 90 or 180 min, depending on the GPCRs being tested. Cell lysis and detec-
tion reagents were subsequently added and one hour later, luminescence measurement taken using a 
PerkinElmer Envision microplate reader. For the GPCRMax panel, % Agonist activity is calculated as 
100% x (mean of test sample - mean of vehicle control) / (mean MAX control ligand - Mean of vehicle 
control). For the OrphanMax panel, % Agonist activity is calculated as 100% x (mean of test sample - 
mean of vehicle control) / (mean of vehicle control). A complete list of GPCRs tested can be found as 
Supplementary data S1 online.
Results
The CB2 selective agonists JWH133 and HU308 are chemoattractants for bio-gel elicited 
PECs. To initially address whether CB2 selective agonists are capable of inducing directed migration of 
murine PECs, we utilised the conventional modified Boyden chamber chemotaxis assay. Figure 1A shows 
that the classical, widely used and potent CB2 agonist JWH133 significantly induced PEC migration 
(P < 0.001 compared to vehicle alone). In contrast, our own novel and selective CB2 agonist, DIAS230, did 
not induce PEC chemotaxis regardless of the concentration used. DIAS2 had no effect on cell viability 
at all of the concentrations used (data not shown), ruling out toxicity as an explanation for the absence 
of migration.
As a chemotaxis methodology the modified Boyden chamber has a number of limitations, chief 
among these being the ability to only measure migration at a single time point. To overcome this issue, 
we employed a novel chemotaxis technology that allows cellular migration to be followed in real-time. 
This is achieved by measuring electrical impedance across a gold electrode that covers the underside of 
a Boyden chamber-style filter. This impedance is converted into a parameter known as Cell Index (CI), 
with increasing CI equating to higher numbers of migrated cells29. Real-time chemotaxis confirmed our 
initial Boyden chamber results, with JWH133 (10 μ M) eliciting a ~ 2 fold increase in CI versus vehicle 
alone, with peak CI reached at ~ 1.5 hours. DIAS2 (10 μ M) remained negative, displaying similar kinetics 
to vehicle alone (Fig.  1B). Alongside JWH133, we also examined whether HU308, a non-classical CB2 
agonist, could also act as a chemoattractant for murine PECs. Real-time analysis showed that HU308 
(10 μ M) did indeed cause chemotaxis with similar kinetics and efficacy to JWH133 (Fig. 1B). Compared 
to the chemokine CCL5 (5 nM), both JWH133 and HU308 displayed similar chemotaxis kinetics and 
maximal responses, albeit with reduced potency (Fig. 1B). Further analysis of these ligands demonstrated 
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that JWH133 did not induce fugetaxis (migration away from a soluble ligand - top chamber: 10 μ M can-
nabinoid, bottom chamber: vehicle) or chemokinesis (non-directional migration stimulated by a soluble 
ligand - 10 μ M cannabinoid in top and bottom chamber), as migration kinetics under these conditions 
closely mimicked vehicle alone (Fig.  1C). Analogous results were also obtained with HU308 (data not 
shown). Moreover, JWH133 and HU308 induced chemotaxis in a concentration dependent manner 
(Fig. 1D,E, respectively). Taken together, these experiments demonstrate that JWH133 and HU308 are 
true chemoattractants for primary murine PECs, whereas our novel CB2 agonist, DIAS2, is not.
In order to corroborate these findings, we employed another impedance based assay that monitors 
cytoskeletal rearrangements which occur downstream of receptor activation in real-time31–33, thereby 
providing an independent, but complementary, functional readout to chemotaxis. The representative 
traces shown in Fig.  1F demonstrate that JWH133 elicited concentration dependent increases in CI. 
Concentration response analysis determined EC50 values of 5.3 and 1.6 μ M for JWH133 and HU308, 
respectively (Fig.  1G). DIAS2 was negative at all concentrations tested, corroborating the chemotaxis 
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Figure 1. The CB2 selective agonists JWH133, HU308 and DIAS2 differ in their ability to induce the 
directional migration of murine PECs. (A) Bio-gel elicited murine PECs were placed into the top well of a 
modified 96 well Boyden chamber (8 μ m pore size) and allowed to migrate towards vehicle or cannabinoid 
for 4 hours at 37 °C, 5% CO2. JWH133 (10 μ M) significantly induced macrophage chemotaxis; however 
DIAS2 had no effect on macrophage migration. Data are mean± SEM, n = 3 biological replicates. (B-E) 
Bio-gel elicited murine PECs were placed into the upper chamber of a CIM-16 plate and allowed to migrate 
for 3-4 hours at 37 °C, 5% CO2 towards indicated compounds. (B) Real-time chemotaxis analysis confirmed 
that JWH133 and HU308, but not DIAS2 (all 10 μ M), elicit PEC chemotaxis. (C) Chemokinetic analysis, 
comparing all combinations of vehicle or cannabinoid (10 μ M) in the top (T) and bottom (B) chambers, 
demonstrated that JWH133 induced true chemotaxis. Data are mean real-time traces from one experiment 
with 4 technical replicates per condition, and are representative of 2 independent biological replicates. 
(D,E) Concentration response analysis found that both JWH133 and HU308 elicit PEC chemotaxis in 
a concentration dependent manner. Data are mean ± SEM, n = 4 biological replicates with 3-4 technical 
replicates per condition. (F,G) Bio-gel elicited PECs were placed into a 96 well E-plate allowed to adhere 
for 2-3 hours at 37 °C, 5% CO2. Afterwards, cells were stimulated with either vehicle or cannabinoid at 
the indicated concentration. (F) Representative raw traces showing cell responses to JWH133 (30, 10, 
3 and 1 μ M). Data are mean traces from one experiment with 2-3 technical replicates per condition. 
(G) Concentration response quantification demonstrates that JWH133 and HU308 caused macrophage 
cytoskeletal rearrangement in a concentration dependent manner, with EC50 values of 5.3 and 1.6 μ M. Data 
are mean ± SEM, n = 3 biological replicates with 2-3 technical replicates per condition. Statistical analysis 
was conducted by one-way ANOVA with Dunnett’s multiple comparisons correction. * P < 0.05, ** P < 0.01 
*** P < 0.001, comparing all samples to vehicle control.
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results (Fig. 1G). In summary, only the chemotaxis positive compounds were capable of inducing changes 
in cell morphology as measured by changes in electrical impedance.
Macrophages are the predominant population in bio-gel elicited PECs that are being meas-
ured in real-time chemotaxis. We initially selected bio-gel as our eliciting agent as the literature 
suggests that this method allows recovery of large cell numbers with 50-60% macrophage purity34. 
However, after analysing the cell populations elicited by bio-gel using flow cytometry, we reproduci-
bly found that neutrophils (F4/80-,7/4+) were the predominant cell population (Fig.  2A). Both mac-
rophages (F4/80+,7/4-) and monocytes (F4/80+,7/4+) formed minor populations and the large neutrophil 
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Figure 2. Macrophages are the dominant cell population in bio-gel elicited PECs that migrate toward 
CB2 agonists. (A) Flow cytometry analysis demonstrates that neutrophils (F4/80-, 7/4+) are the major cell 
population within bio-gel elicited PECs, whereas macrophages (F4/80+, 7/4-) and monocytes (F4/80+, 7/4+) 
form only a minor population. (B) Bio-gel elicited PECs were placed into petri dishes and allowed to adhere 
for 2 hours at 37 °C, 5% CO2 prior to washing with PBS. Cells were then left overnight at 37 °C, 5% CO2 and 
remaining adherent cells removed using PBS containing 10 mM EDTA. Flow cytometry analysis of these 
cells after staining with F4/80 and 7/4 demonstrates that this process strongly enriches macrophages and 
removes neutrophils. (C) Enriched macrophages (2 × 105) were placed into the upper chamber of a CIM-16 
plate and allowed to migrate for 4 hours at 37 °C, 5% CO2 toward vehicle (0.3% DMSO), 5 nM chemokine 
or 10 μ M cannabinoid. Real-time chemotaxis analysis demonstrates that JWH133 and HU308 caused 
strong directed migration of this macrophage population. Data show mean trace of 3-4 technical replicates 
per condition. (D) Flow cytometry analysis using F4/80 and 7/4 demonstrates that macrophages are the 
main cell population elicited by intraperitoneal injection of 4% thioglycollate. (E,F) Thioglycollate elicited 
macrophages (2 × 105) were placed into the upper chamber of a CIM-16 plate and allowed to migrate for 
4 hours at 37 °C, 5% CO2 toward vehicle (0.3% DMSO) or 10 μ M cannabinoid. (E) Representative real-time 
chemotaxis trace of thioglycollate elicited macrophage migration towards JWH133, HU308 or vehicle. Data 
show mean trace of 3-4 technical replicates per condition. (F) Quantification of chemotaxis demonstrates 
that JWH133 and HU308 significantly induced thioglycollate elicited macrophage chemotaxis. Data are 
mean ± SEM, n = 4-6 biological replicates with 3-4 technical replicates per condition. Statistical analysis was 
conducted by one-way ANOVA with Dunnett’s multiple comparisons correction. * P < 0.05, ** P < 0.01, 
comparing all samples to vehicle control.
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population persisted when a different batch of bio-gel or animals housed in a different facility were 
used (data not shown). However, neutrophils are unlikely to contribute to the observed CI signal when 
using bio-gel PECs in the real-time chemotaxis system, as migration of highly pure bone marrow neu-
trophils towards the anaphylatoxin C5a, a well know neutrophil chemoattractant35, yields an absolute 
CI signal of less than 0.08 (data not shown). It is important to note that this does not mean neutrophils 
do not migrate towards the cannabinoids, it simply means that these cells are not measured by the 
real-time system and can therefore be discounted as a population that contributes to the CI observed. 
Instead, real-time chemotaxis analysis of macrophages enriched from bio-gel PECs by overnight plating 
(~85% macrophage and < 1% neutrophil; Fig. 2B), demonstrated that both JWH133 and HU308 (10 μ M) 
robustly induced directed migration of this enriched macrophage population. CCL5 (5 nM) was used as 
a positive control. To further probe the ability of macrophages to migrate towards JWH133 and HU308, 
we next used thioglycollate elicitation that yielded a large macrophage population (~70%) with minimal 
neutrophils (Fig.  2D). Quantification of real-time chemotaxis found that JWH133 and HU308 signifi-
cantly induced thioglycollate elicited macrophage chemotaxis (Fig. 2F; P = 0.0024 and 0.00161, respec-
tively). A representative real-time chemotaxis trace is shown in Fig. 2E. Together this data demonstrates 
that macrophages can migrate towards JWH133 and HU308 and these are the predominant population 
in bio-gel elicited PECs that are being measured in real-time chemotaxis analysis.
Only a subset of CB2 agonists act as chemoattractants for murine macrophages. In order 
to examine the scope of CB2 agonist-induced chemotaxis, we expanded our list of ligands to include 
a range of widely used and commercially available compounds active at CB2. Based on our data with 
JWH133 and HU308, we selected 10 μ M as the initial screening concentration, as this caused robust 
and reproducible chemotaxis. As shown in Fig. 3A, CB2 agonists fall into two distinct classes, with the 
majority (8/12 ligands tested) unable to induce chemotaxis. Nonetheless, alongside JWH133 and HU308, 
which significantly induced chemotaxis by 2 and 2.3 fold respectively (P < 0.001 versus vehicle), we 
discovered that the classical cannabinoids L-759,656 and L-759,633 also acted as macrophage chemoat-
tractants (P < 0.001 versus vehicle). As shown in the representative traces, L-759,656 (10 and 1 μ M) and 
L-759,633 (10 μ M) gave robust increases in CI versus cells migrating towards vehicle alone (Fig. 3B,C). 
Kinetically, these compounds differed with respect to JWH133 and HU308 eliciting a slower chemotactic 
response, with peak CI reached between 2-2.5 hours. Furthermore, they were slightly less efficacious, 
inducing chemotaxis 1.7 (L-759,656) and 1.6 (L-759,633) fold versus vehicle. The aminoalkylindoles, 
(WIN55,212-2, JWH015, AM1241 and GW405833), the non-classical cannabinoid CP55,940, the tricy-
clic pyrazole GP1a, the endocannabinoid 2-AG and our novel CB2 agonist DIAS2 were all found to be 
negative for chemotaxis (Fig. 3A). The structures of all the compounds used in this study can be found in 
supplementary Fig. S1. Concentration response analysis conducted for AM1241, GP1a, GW405833 and 
CP55,940 (3-fold series from 30 μ M to 100 nM) found that these agonists did not elicit chemotaxis at any 
concentration tested (data not shown). Real-time analysis of changes in cell morphology demonstrated 
that L-759,656 induced concentration dependent signalling (Fig. 3D), whereas the chemotaxis negative 
compounds CP55,950, AM1241 (Fig. 3D), GP1a and WIN55212-2 (Fig. 3E) did not induce signalling at 
any concentration tested. In summary, using both Boyden chamber and real-time chemotaxis assays we 
have shown that only a subset of CB2 agonists act as primary murine macrophage chemoattractants and 
only chemotaxis positive compounds were capable of inducing changes in cell morphology as measured 
by changes in electrical impedance.
CB2 selective agonists induce primary chemotaxis independent of CB2. To examine the reli-
ance of CB2 agonist-induced migration on G protein activation, bio-gel elicited PECs were incubated 
with 200 ng/ml pertussis toxin (PTX) for 90 min prior to real-time chemotaxis analysis. Following 
pre-treatment, migration towards JWH133, HU308 and L-759,656 (all 10 μ M) was significantly inhib-
ited. Chemerin (5 nM), a chemoattractant protein36, was used as a PTX control. (Fig.  4A; Chemerin, 
JWH133 and HU308, P < 0.001; L-759,656, P = 0.0039), demonstrating that chemotaxis towards CB2 
agonists absolutely requires Gi/o activation. We then used SR144528 (a widely used CB2 inverse agonist) 
to pharmacologically probe chemotaxis reliance on CB2 signalling. Surprisingly, pre-treatment with 1 μ M 
SR144428 had no effect on macrophage chemotaxis towards JWH133 and HU308 (Fig.  4B). However, 
SR144528 did cause a significant 30% increase in PEC migration toward 5 nM CCL5 (P = 0.01). To rule 
out inactivity at CB2, we tested the ability of SR144528 to antagonise JWH133 and HU308-induced 
CB2 activation by measuring cAMP levels in CHO cells expressing the CB2. In our hands, JWH133 and 
HU308 acted as agonists at all concentrations (P < 0.001 versus vehicle plus Forskolin (FSK) alone), 
whereas SR144528 alone (1 μ M) acted as an inverse agonist, significantly increasing FSK-induced cAMP 
levels (Fig.  4C,D; P < 0.001). Pre-incubation with SR144528 for 30 min prior to agonist addition sig-
nificantly reversed JWH133 and HU308-induced CB2 activation at 10, 3 and 1 μ M (Fig.  4C,D, respec-
tively). To further study the ability of SR144528 to antagonise JWH133 and HU308-induced signalling 
we examined ERK1/2 phosphorylation in bio-gel elicited enriched macrophages, as CB2 agonism has 
been previously reported to activate the MAPK pathway5,6. Compared to vehicle, JWH133 and HU308 
(10 μ M) both caused substantial ERK1/2 phosphorylation, which SR144528 (1 μ M) pre-treatment was 
unable to reverse (Fig.  4E). SR144528 alone gave no increase in the levels of phospho-ERK1/2. Total 
ERK1/2 levels confirmed equal protein loading across all samples. Although bio-gel elicited macrophages 
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Figure 3. Only a subset of CB2 agonists are primary macrophage chemoattractants. (A-C) Bio-gel elicited 
murine PECs (4 × 105) were placed into the upper chamber of a CIM-16 plate and allowed to migrate for 
3-4 hours at 37 °C, 5% CO2 toward vehicle (0.3% DMSO), 5 nM chemokine or 10 μ M cannabinoid. (A) 
Chemotaxis was measured as maximum cell index minus starting cell index and data are displayed as a 
fold change compared to cells migrating towards vehicle. Only CCL5, JWH133, HU308, L-759,656 and 
L-759,633 acted as chemoattractants. 2-AG was used at a concentration of 15 μ M. Data are mean ± SEM, 
n = 3-26 biological replicates with 3-4 technical replicates per condition. (B and C) Representative traces 
of chemotaxis positive and chemotaxis negative CB2 agonists. Data show mean trace of 3-4 technical 
replicates per condition. Statistical analysis was conducted by one-way ANOVA with Dunnett’s multiple 
comparisons correction. ns P > 0.05, *** P < 0.001, comparing all samples to vehicle control. (D,E) Bio-
gel elicited PECs (5 × 104) were placed into a 96 well E-plate allowed to adhere for 2-3 hours at 37 °C, 5% 
CO2. Afterwards, cells were stimulated with either vehicle (0.3% DMSO) or cannabinoid. (D) Concentration 
response quantification demonstrates that L-759,656 caused cytoskeletal rearrangement in a concentration 
dependent manner, with an EC50 value of 7.3 μ M. In contrast, (D) CP55,940, AM1241, (E) GP1a and 
WIN55,212-2 failed to elicit a response at any concentration (JWH133 curve is shown for comparison). Data 
are mean ± SEM, n = 3 biological replicates with 2-3 technical replicates per condition.
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Figure 4. Chemotaxis towards CB2 selective agonists is blocked by pertussis toxin, but not by CB2 or 
CB1 inverse agonists. Bio-gel elicited PECs were incubated with either vehicle, (A) 200 ng/ml pertussis 
toxin (PTX) for 90 min or (B) 1 μ M SR144528 for 30 min at 37 °C, 5% CO2. Following treatment, cells 
were allowed to migrate for 3-4 hours at 37 °C, 5% CO2 toward vehicle, 5 nM chemerin, 5 nM CCL5 or 
10 μ M cannabinoid. For experiments using SR144528, 1 μ M was added in the lower chamber alongside the 
indicated chemoattractant. Data are mean ± SEM, (A) n = 4-11, (B) n = 3-10 biological replicates with 3-4 
technical replicates per condition. (C,D) CHO-K1 cells expressing human CB2 were incubated for 30 min 
at 37 °C, 5% CO2 with either vehicle or SR144528 (1 μ M - final assay concentration). Following treatment, 
vehicle, JWH133 (C) or HU308 (D) was added in assay buffer containing forskolin (FSK – 20 μ M final 
assay concentration) to give the indicated final concentrations. The cells were then incubated for 30 min 
at 37 °C, 5% CO2 before the addition of the detection reagents. Data are mean ± SEM, n = 6. (E) Enriched 
macrophages were stimulated with either vehicle, or 10 μ M cannabinoid in the presence and absence of 1 μ M 
SR144528. Relative levels of phosphorylated ERK1/2 and total ERK1/2 were determined by western blotting. 
Blot is representative of n = 3 independent biological replicates. (F) Bio-gel elicited murine PECs were 
incubated with either vehicle or 1 μ M SR141716A for 30 min at 37 °C, 5% CO2. Following treatment, cells 
were allowed to migrate for 3-4 hours at 37 °C, 5% CO2 toward vehicle or 10 μ M cannabinoid. SR141716A 
at 1 μ M was added in the lower chamber alongside the indicated cannabinoid. Data are mean ± SEM, 
n = 4 biological replicates with 3-4 technical replicates per condition. For all data, statistical analysis was 
conducted by two-way ANOVA with Sidak’s multiple comparisons correction. ns P > 0.05, * P < 0.05, ** 
P < 0.01, *** P < 0.001, for indicated comparisons. ††† P < 0.001, compared to vehicle + FSK alone.
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do not express CB1 mRNA (data not shown), we wanted to confirm that CB1 was not responsible for CB2 
agonist-induced macrophage chemotaxis. Pre-treatment with 1 μ M SR141716A (a CB1 receptor inverse 
agonist) for 30 min prior to real-time chemotaxis analysis had no effect on JWH133 or HU308-induced 
chemotaxis (Fig. 4F). SR141716A alone did not affect migration.
To conclusively establish whether CB2 agonist-induced macrophage chemotaxis occurs independently 
of CB2, real-time chemotaxis analysis was conducted using bio-gel elicited PECs isolated from CB2 null 
mice (B6.129P2-Cnr2tm1Dgen/J mice from Jackson laboratories). Remarkably, 10 μ M JWH133, HU308 
and L-759,656 significantly induced CB2-/- macrophage chemotaxis (Fig.  5B; P = 0.0045, P < 0.001 and 
P = 0.0027, respectively). As demonstrated by the real-time traces in Fig. 5A, JWH133 and HU308 retained 
similar kinetic chemotaxis profiles compared to WT cells. Comparable results were also obtained for 
L-759,656 and L-759,633 (data not shown). Pre-treatment of CB2-/- macrophage with PTX significantly 
inhibited chemotaxis to both JWH133 and HU308 (Fig.  5C; P = 0.022 and P = 0.0034, respectively). 
Following this result, we wanted to examine whether JWH133 and HU308 could still activate intracel-
lular signalling in the absence of CB2. Stimulation of bio-gel elicited enriched CB2-/- macrophages with 
10 μ M JWH133 or HU308 resulted in a significant increase in the levels of phospho-ERK1/2 (Fig. 5D). 
Chemotaxis positive CB2 agonists retained their ability to induce cytoskeletal rearrangements in CB2-/- 
macrophage, whereas chemotaxis negative agonists had no effect, replicating the WT results (Fig.  5E). 
Quantification of JWH133 and HU308 activity at 10 μ M is shown in Fig. 5F (P < 0.001 and P = 0.0032, 
respectively compared to vehicle alone). Taken together, our results demonstrate that JWH133 and 
HU308 activate a Gi/o-coupled receptor, which is not CB2, to elicit cytoskeletal rearrangement and 
directed macrophage migration.
The candidate cannabinoid receptors GPR18 and GPR55 are not responsible for the off-target 
effects of JWH133 and HU308. A body of literature exists implicating both GPR18 and GPR55 as 
potential cannabinoid receptors37–40. Additionally, activation of GPR55 by L-α -lysophosphatidylinositol 
causes the directed migration of human breast cancer cells41 and GPR18 has been shown to mediate 
2-AG-induced chemotaxis of a microglial cell line42. Since both receptors are expressed in bio-gel elicited 
macrophages (Table 1), we set out to determine whether either was responsible for the off-target effects 
of JWH133 and HU308. N-terminal tagged receptor constructs were transfected into CHO cells using 
electroporation and surface receptor levels determined by flow cytometry after approximately 16 hours. 
In comparison to cells transfected with empty vector (blue histogram), CB2 (Fig. 6A), GPR18 (Fig. 6B) 
and GPR55 (Fig. 6C) transfected cells all had significant surface expression (red histogram), which was 
comparable across all three GPCRs (~50% positive). C5aR1 transfected CHO cells (selected as a positive 
control) had very high surface receptor levels (Fig.  6D; ~ 75% positive) and this was confirmed using 
an antibody that specifically recognises C5aR1 (data not shown). We then measured the ability of the 
chemotaxis positive agonists JWH133 and HU308, the chemotaxis negative ligand CP55,940 and C5a 
to induce cytoskeletal rearrangement in receptor transfected cells. Stimulation of transfected cells with 
10 nM C5a (Representative ECIS trace – Fig.  6E) only elicited significant positive signalling in C5aR1 
transfected cells (Fig. 6H; P < 0.0001, compared to empty vector transfected cells), confirming the assay 
worked as intended. Stimulation of cells with 10 μ M JWH133 (Fig. 6F,I), HU308 (Fig. 6G,J) or CP55,940 
(Fig.  6K) only caused significant cytoskeletal rearrangement in CB2 transfected cells (P < 0.0001 – 
JWH133; P = 0.0007 – HU308; P = 0.0186 – CP55,940; all in comparison to empty vector transfected 
cells). Abnormal cannabidiol (Abn-CBD) caused no response in any of the receptor transfected cells 
(Fig. 6L). Taken together, our data suggest that GPR18 and GPR55 are not responsible for the off-target 
effects of JWH133 and HU308.
In an attempt to find the receptor responsible for CB2 agonist-induced macrophage chemotaxis, we 
tested the ability of JWH133 (10 μ M) to induce β -arrestin recruitment at 241 GPCRs using the Discoverx 
PathHunter® eXpress β -Arrestin GPCR Assay system. The screen was split into two panels, the first being 
GPCRMax, which contains CHO cells transfected with GPCRs that have well characterised agonists 
(Fig. 7A – 168 receptors) and the second being OrphanMax, which contains orphan GPCRs (Fig. 7B – 
73 receptors). Both reassuringly and unfortunately, JWH133 only gave robust β -arrestin recruitment in 
CB1 and CB2 transfected CHO cells (Fig.  7A). Additionally, JWH133 was unable to induce β -arrestin 
recruitment in GPR18 and GPR55 transfected CHO cells (Fig. 7B). The full list of GPCRs tested and the 
assay results can be found as Supplementary data S1 online.
Discussion
To our knowledge, this is the first study to address whether activation of CB2 causes the directed migra-
tion of primary murine macrophages. Using real-time measurements of both cell morphology and 
migration, we showed that only a subset of CB2 agonists act as chemoattractants for primary murine 
macrophages. Furthermore, we found that although CB2 agonist-induced chemotaxis was PTX sensitive, 
pharmacological inhibition or genetic ablation of CB2 had no effect on cellular signalling or macrophage 
migration. Therefore, this provides the first evidence that the widely used CB2 agonists JWH133, HU308, 
L-759,656 and L-759,633 have off-target effects at a non-CB1/CB2 Gi/o-coupled GPCR; a finding that has 
wide ranging implications for the entire cannabinoid field. Finally, our data conclusively demonstrate that 
CB2 is not a macrophage chemoattractant receptor.
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Figure 5. JWH133, HU308 and L-759,656 act as chemoattractants for CB2-/- primary murine macrophages. 
Bio-gel elicited murine PECs from CB2-/- mice were placed into the upper chamber of a CIM-16 plate and allowed 
to migrate for 3-4 hours at 37 °C, 5% CO2 toward vehicle (0.3% DMSO), 5 nM CCL5 or 10 μ M cannabinoid. (A) 
Representative trace showing that the chemotaxis-positive CB2 agonists remain chemoattractants for CB2-/- murine 
macrophages. (B) Quantification of chemotaxis demonstrates that CCL5 (5 nM), JWH133, HU308 and L-759,656 
(all 10 μ M) significantly induced CB2-/- macrophage chemotaxis. Data are mean ± SEM, n = 5-15 biological replicates 
with 3-4 technical replicates per condition. (C) Pre-treatment of CB2-/- bio-gel elicited macrophages with PTX 
(200 ng/ml, 90 min at 37 °C, 5% CO2) significantly reduced JWH133 and HU308-induced chemotaxis (both 10 μ M). 
Data are mean ± SEM, n = 3 biological replicates with 2-3 technical replicates per condition. (D) Bio-gel elicited 
CB2-/- macrophages were stimulated with either vehicle (0.3% DMSO) or 10 μ M cannabinoid. Relative levels of 
phosphorylated ERK1/2 and total ERK1/2 were determined by western blotting and densitometric analysis confirmed 
that JWH133 and HU308 significantly elicited ERK1/2 phosphorylation. Data are mean ± SEM, n = 6 biological 
replicates. A representative phospho-ERK1/2 blot is shown as an insert. (E,F) Bio-gel elicited CB2-/- macrophages 
were placed into a 96 well E-plate allowed to adhere for 2-3 hours at 37 °C, 5% CO2. Afterwards, cells were stimulated 
with either vehicle (0.3% DMSO) or cannabinoid (10 μ M). (E) Representative trace showing the kinetics of CB2 
agonist-induced cytoskeletal rearrangements. (F) Quantification demonstrates that JWH133 and HU308 significantly 
elicited cell spreading in CB2-/- murine macrophages. Data are mean ± SEM, n = 4-5 biological replicates with 3-4 
technical replicates per condition. For B,D,F statistical analysis was conducted by one-way ANOVA with Dunnett’s 
multiple comparisons correction. For C statistical analysis was conducted by two-way ANOVA with Sidak’s multiple 
comparisons correction * P < 0.05, ** P < 0.01, *** P < 0.001, comparing all samples to vehicle control.
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We are confident that throughout the study we were measuring macrophage chemotaxis, despite the 
fact that the bio-gel elicited PECs were comprised mostly of neutrophils. Without enrichment 4 × 105 
bio-gel elicited PECs were used per chemotaxis well and CI signals for JWH133 and HU308 peak at 
approximately 0.4. After macrophage enrichment of bio-gel elicited PECs, only 2 × 105 cells are used per 
well, yet JWH133 and HU308 reach peak CIs of approximately 0.8 and retain similar kinetic profiles to 
normal bio-gel elicited PECs. Furthermore, thioglycollate elicited macrophages used at 2 × 105 cells per 
well display chemotaxis kinetics and peak CI signals similar to the enriched macrophages. Importantly, 
the thioglycollate elicited macrophages did not contain neutrophils. Finally, neutrophils isolated from 
bone marrow only elicit a weak CI signal in real-time chemotaxis when migrating towards the potent 
neutrophil chemoattractant C5a. Therefore in bio-gel elicited PECs, neutrophils likely contribute only a 
negligible component to the observed CI signal as they do not score in the real-time chemotaxis system.
Initially we assumed that the ability of only a subset of CB2 agonists to induce macrophage chem-
otaxis was due to functional selectivity. This phenomenon, whereby ligands at the same receptor can 
activate distinct downstream signalling pathways18, is well documented for CB2 agonists acting at CB219,20 
and previous studies demonstrating that 2-AG acts as a chemoattractant, also found that that the syn-
thetic CB2 agonists WIN55,212-2 and CP55,940 failed to elicit any migratory response14,17. However, 
this hypothesis was proved incorrect as CB2 agonist-induced macrophage chemotaxis was unaffected by 
pharmacological inhibition or genetic deletion of CB2. Instead our results demonstrate that the synthetic 
CB2 agonists JWH133, HU308, L-759,656 and L-759,633 activate at least one Gi/o-coupled receptor dis-
tinct from CB2, to elicit directed cellular migration. This finding is not without precedent, as a non-CB1/
CB2 receptor has been implicated in the negative regulation of fMLP-induced chemotaxis by endo and 
phytocannabinoids27. The profile of the receptor identified by McHugh et al does not match the putative 
GPCR from our study, however their observation demonstrates that novel receptors involved in chemo-
taxis modulation by cannabinoids may be more numerous than presently thought.
Chemical analysis of the agonists used in this study provides further support that JWH133, HU308, 
L-759,656 and L-759,633 have a specific mechanism at an off-target site. The chemotaxis positive com-
pounds are all structurally related, being based on the phytocannabinoid Δ 9-THC, and also have cLogP 
values in excess of 6.7 (Supplementary Fig. S1). As similar compounds normally have similar biological 
activity43, this implies that they share a common mode of action. However as CP55,940, which has a 
similar structure and lipophilicity to the chemotaxis positive compounds, was unable to induce directed 
migration, it is unlikely that the ability of only some CB2 ligands to induce chemotaxis relies solely on 
their physicochemical properties. Instead we conclude that CP55,940 likely violates the steric constraints 
of the off-target site rendering it inactive and unable to induce directed migration.
Currently the identity of the receptor responsible for CB2 agonist-induced chemotaxis remains 
unknown, however we initially ruled out CB1 as it was not expressed on bio-gel elicited macrophages 
and SR141617A had no effect on CB2 agonist-induced chemotaxis. We next focussed on GPR55 and 
GPR18 as potential candidates, as both bind numerous cannabinoid compounds37,39,40 and have been 
shown to mediate directed cellular migration38,41,42. We elected to use electrical impedance measurement 
of cell morphology changes as this system correlated strongly with chemotaxis and also allows for mul-
tiple receptors and agonists to be tested simultaneously. Nonetheless, JWH133 and HU308 were unable 
to induce cytoskeletal rearrangements in CHO cells expressing GPR18 or GPR55. Furthermore, JWH133 
did not elicit β -arrestin recruitment at either receptor. Consequently, both were ruled out as the GPCR 
in question.
It is important to note that the negative result from the β -arrestin screen does not conclusively prove 
that none of the 241 GPCRs tested are responsible for the off-target effects of the synthetic CB2 agonists 
and should be viewed with respect to the following caveats. Firstly, functional selectivity may mean that 
JWH133 does not cause β -arrestin recruitment at this particular GPCR. Secondly, as human GPCRs 
were used for the screen (as murine versions were not available) species differences between CB2 phar-
macology, which have been well documented in vitro44–46, could explain the negative result. However, as 
JWH133 has already been shown to act as a chemoattractant for human monocytes, at the same concen-
trations used in this study, we assumed that this would likely not be an issue13. Finally, recent work has 
Gene Mean Ct value SEM
Actin 14.09 0.305
CB2 22.52 0.5536
GPR55 25.72 0.1437
GPR18 22.01 0.3132
Table 1. Bio-gel elicited macrophages express CB2, GPR55 and GPR18. Expression of CB2, GPR55 and 
GPR18, alongside the reference gene actin, was determined by real-time PCR using 500 ng of cDNA per 
reaction with the following thermal profile: 95 °C for 5 min, 40 cycles of 95 °C for 30 s, 60 °C for 20 s, 72 °C 
for 30 s and a final step of 72 °C for 5 min. Mean threshold cycle (Ct) value and SEM were calculated from 
n = 4 biological replicates.
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Figure 6. JWH133 and HU308 do not elicit cytoskeletal rearrangements in CHO cells expressing 
murine GPR18 or GPR55. CHO cells (1 × 106) were mixed with 2 μ g of empty or GPCR-containing vector, 
transfected via electroporation and left overnight at 37 °C, 5% CO2 to allow tagged GPCR expression. (A-
D) GPCR surface levels were determined by flow cytometry and representative histograms are shown. 
Cells transfected with empty vector alone were used to determine non-specific antibody staining. (A) 
FLAG-CB2, (B) HA-GPR18 and c-Myc-GPR55 (C) all had similar expression levels. (D) HA-C5aR1 was 
used as a positive control and displayed high surface levels. (E-L) Transfected CHO cells were plated into a 
96 well E-plate (25,000 cells/well) and left overnight at 37 °C, 5% CO2 to reach a stable baseline. Afterwards, 
cells were stimulated with either vehicle (0.3% DMSO), C5a (10 nM) or cannabinoid (10 μ M). (H) 
Quantification of C5a-induced responses found that only C5aR1 transfected cells responded to C5a (10 nM; 
E – Representative trace). JWH133 (F,I), HU308 (G,J) and CP55,940 (K) only caused significant responses 
in CB2 transfected cells. Importantly, cells transfected with GPR18 or GPR55 did not respond to either 
JWH133 or HU308 (I,J). Abnormal cannabidiol (Abn-CBD; 10 μ M) did not elicit a response in any of the 
GPCR transfected cells (L). Data are mean ± SEM, n = 3-6 biological replicates with 2-3 technical replicates 
per condition. Statistical analysis was conducted by one-way ANOVA with Dunnett’s multiple comparisons 
correction. * P < 0.05, *** P < 0.001, comparing all samples to empty vector transfected cells.
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shown that established CB2 ligands can behave differently in primary tissue as opposed to recombinant 
cellular systems as in human, rat and mouse spleen, AM1241 behaves as an agonist, whereas in CHO 
cells overexpressing human CB2 it acts as an inverse agonist47. Therefore although the CB2 ligands are 
acting as agonists for the novel GPCR in primary murine macrophages, they may display different phar-
macology in the in vitro system used for the β -arrestin screen.
Regardless of the exact nature of the receptor, we believe our finding that JWH133, HU308, L-759,656 
and L-759,633 are more promiscuous than currently thought has wide-ranging implications for the can-
nabinoid field as a whole. Numerous endogenous and plant derived cannabinoids have been shown 
to activate a multitude of receptors other than CB1 or CB2, however to our knowledge this is the first 
report that these synthetic agonists have off-target effects of functional consequence in disease relevant 
primary cells. This is of importance as JWH133 and HU308 are among the agonists most frequently 
used to assess the selective activation of CB22. However their reputation as selective agonists, cemented 
by historical compound characterisation for CB1/CB2 activity in transfected cell systems overexpressing 
either cannabinoid receptor, has meant that many studies do not employ stringent controls when using 
these ligands. A cursory search of the literature found multiple examples of JWH133 and HU308 being 
used in both primary cell assays and in vivo disease models without receptor antagonism or CB2 deletion 
to confirm CB2 dependence48–57. The off-target effects of JWH133 and HU308 may mean that results 
obtained in these studies have been erroneously attributed solely to the activation of CB2. Additionally, 
many of the above models have a strong inflammatory component and as macrophages are key players 
during inflammation58,59, the macrophage localised GPCR implicated in this study has likely confounded 
observed results. Indeed this receptor may even explain current findings in the literature. For example, 
the previously mentioned ability of JWH133 to be a chemoattractant for human monocytes was not 
confirmed to absolutely depend on CB213. In light of our data we speculate that, rather than CB2, the 
novel receptor implicated in our study may be responsible for JWH133-mediated chemotaxis of human 
monocytes.
In summary our work emphasises the importance of using primary cells wherever possible, as although 
in vitro cell systems have undoubtedly proved crucial for our understanding of CB1 and CB2 pharmacol-
ogy, by their very nature they will not elucidate the targets and pharmacology of CB2 agonists in phys-
iologically relevant settings. Furthermore, it is critical that genetic knockout alongside pharmacological 
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Figure 7. Out of 241 GPCRs, JWH133 only elicits β-arrestin recruitment at CB1 and CB2. JWH133 
(10 μ M) was tested for its ability to induce β -arrestin recruitment at 241 GPCRs, split over two panels, using 
the Discoverx PathHunter® eXpress β -Arrestin GPCR Assay system. (A) The GPCRMax panel was comprised 
of GPCRs with known and validated ligands. For this panel % Agonist activity is calculated as 100% x (mean 
of test sample - mean of vehicle control) / (mean MAX control ligand - Mean of vehicle control). JWH133 
only caused β -arrestin recruitment at CB1 and CB2. (B) The OrphanMax panel was comprised of GPCRs 
without validated ligands. For this panel % Agonist activity is calculated as 100% x (mean of test sample - 
mean of vehicle control) / (mean of vehicle control). JWH133 did not elicit β -arrestin recruitment at either 
GPR18 or GPR55. Data are mean of technical duplicates.
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blockade should be used wherever possible when seeking evidence of a CB2 specific effect using primary 
cells, tissues or in vivo disease models.
References
1. Pertwee, R. G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147 (Suppl 1),  S163–171, doi:10.1038/
sj.bjp.0706406 (2006).
2. Pertwee, R. G. et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: 
beyond CB(1) and CB(2). Pharmacol. Rev. 62, 588–631, doi:10.1124/pr.110.003004 (2010).
3. Pertwee, R. G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. (Lond) 30 (Suppl 1), 
S13–18, doi:10.1038/sj.ijo.0803272 (2006).
4. Felder, C. C. et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. 
Mol. Pharmacol. 48, 443–450 (1995).
5. Howlett, A. C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol. 53–79 (2005).
6. Howlett, A. C. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 
161–202 (2002).
7. Mackie, K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 20 (Suppl 1),  10–14, doi:10.1111/j.1365-
2826.2008.01671.x (2008).
8. Galiegue, S. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte 
subpopulations. Eur. J. Biochem. 232, 54–61 (1995).
9. Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L. & Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. Future 
Med. Chem. 1, 1333–1349, doi:10.4155/fmc.09.93 (2009).
10. Basu, S. & Dittel, B. N. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. 
Immunol. Res. 51, 26–38, doi:10.1007/s12026-011-8210-5 (2011).
11. Cabral, G. A. & Griffin-Thomas, L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects 
for neuroinflammation. Expert Rev. Mol. Med. 11, e3, doi:10.1017/S1462399409000957 (2009).
12. Miller, A. M. & Stella, N. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharmacol. 153, 299–308, 
doi:10.1038/sj.bjp.0707523 (2008).
13. Montecucco, F., Burger, F., Mach, F. & Steffens, S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte 
migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 294, H1145–1155, doi:10.1152/
ajpheart.01328.2007 (2008).
14. Jorda, M. A. et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 
2-arachidonoylglycerol. Blood 99, 2786–2793 (2002).
15. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J. Biochem. 137, 
217–223, doi:10.1093/jb/mvi021 (2005).
16. Oka, S. et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human 
eosinophilic leukemia cells and human peripheral blood eosinophils. J. Leukoc. Biol. 76, 1002–1009, doi:10.1189/jlb.0404252 
(2004).
17. Kishimoto, S. et al. 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and 
human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem. 278, 24469–
24475, doi:10.1074/jbc.M301359200 (2003).
18. Kenakin, T. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296–302, doi:10.1124/jpet.110.173948 
(2011).
19. Atwood, B. K., Wager-Miller, J., Haskins, C., Straiker, A. & Mackie, K. Functional selectivity in CB(2) cannabinoid receptor 
signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol. Pharmacol. 81, 250–263, doi:10.1124/
mol.111.074013 (2012).
20. Shoemaker, J. L., Ruckle, M. B., Mayeux, P. R. & Prather, P. L. Agonist-directed trafficking of response by endocannabinoids 
acting at CB2 receptors. J. Pharmacol. Exp. Ther. 315, 828–838, doi:10.1124/jpet.105.089474 (2005).
21. Nathan, C. & Ding, A. Nonresolving inflammation. Cell 140, 871–882, doi:10.1016/j.cell.2010.02.029 (2010).
22. Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166–172, 
doi:10.1126/science.1230720 (2013).
23. Sacerdote, P. et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 
production of murine macrophages both in vivo and in vitro. J. Neuroimmunol. 159, 97–105, doi:10.1016/j.jneuroim.2004.10.003 
(2005).
24. Sacerdote, P., Massi, P., Panerai, A. E. & Parolaro, D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 
decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 109, 
155–163 (2000).
25. Steffens, S. et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782–786, 
doi:10.1038/nature03389 (2005).
26. Raborn, E. S., Marciano-Cabral, F., Buckley, N. E., Martin, B. R. & Cabral, G. A. The cannabinoid delta-9-tetrahydrocannabinol 
mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J. Neuroimmune Pharmacol. 3, 
117–129, doi:10.1007/s11481-007-9077-z (2008).
27. McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R. G. & Ross, R. A. Inhibition of human neutrophil chemotaxis by endogenous 
cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol. Pharmacol. 73, 441–450, doi:10.1124/
mol.107.041863 (2008).
28. Deusch, E. et al. No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear 
leukocytes. J. Neuroimmunol. 141, 99–103 (2003).
29. Iqbal, A. J. et al. A real time chemotaxis assay unveils unique migratory profiles amongst different primary murine macrophages. 
PLoS One 8, e58744, doi:10.1371/journal.pone.0058744 (2013).
30. Gianella-Borradori, M. et al. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. 
Bioorganic & medicinal chemistry 23, 241–263, doi:10.1016/j.bmc.2014.11.002 (2015).
31. Yu, N. et al. Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study 
G protein-coupled receptors. Anal. Chem. 78, 35–43, doi:10.1021/ac051695v (2006).
32. Scrace, S., O’Neill, E., Hammond, E. M. & Pires, I. M. Use of the xCELLigence system for real-time analysis of changes in cellular 
motility and adhesion in physiological conditions. Methods Mol. Biol. 1046, 295–306, doi:10.1007/978-1-62703-538-5_17 (2013).
33. Guan, N. et al. Label-free monitoring of T cell activation by the impedance-based xCELLigence system. Mol. Biosyst. 9, 1035–
1043, doi:10.1039/c3mb25421f (2013).
34. Davies, J. Q. & Gordon, S. Isolation and culture of murine macrophages. Methods Mol. Biol. 290, 91–103 (2005).
35. Harvath, L. Neutrophil chemotactic factors. Exs. 59, 35–52 (1991).
www.nature.com/scientificreports/
17Scientific RepoRts | 5:10682 | DOi: 10.1038/srep10682
36. Cash, J. L. et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. The Journal of experimental 
medicine 205, 767–775, doi:10.1084/jem.20071601 (2008).
37. Console-Bram, L., Brailoiu, E., Brailoiu, G. C., Sharir, H. & Abood, M. E. Activation of GPR18 by cannabinoid compounds: a 
tale of biased agonism. Br. J. Pharmacol. 171, 3908–3917, doi:10.1111/bph.12746 (2014).
38. McHugh, D., Page, J., Dunn, E. & Bradshaw, H. B. Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists 
at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol. 165, 2414–2424, doi:10.1111/
j.1476-5381.2011.01497.x (2012).
39. Ryberg, E. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092–1101, doi:10.1038/
sj.bjp.0707460 (2007).
40. Sharir, H. & Abood, M. E. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 126, 
301–313, doi:10.1016/j.pharmthera.2010.02.004 (2010).
41. Ford, L. A. et al. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and 
polarization of human breast cancer cells. Br. J. Pharmacol. 160, 762–771, doi:10.1111/j.1476-5381.2010.00743.x (2010).
42. McHugh, D. et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through 
GPR18, the putative abnormal cannabidiol receptor. BMC neuroscience 11, 44, doi:10.1186/1471-2202-11-44 (2010).
43. Johnson, M. A. & Maggiora, G. M. Concepts and applications of molecular similarity. (Wiley New York, 1990).
44. Bingham, B. et al. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 
and its resolved enantiomers. Br. J. Pharmacol. 151, 1061–1070, doi:10.1038/sj.bjp.0707303 (2007).
45. Shire, D. et al. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochimica et 
biophysica acta 1307, 132–136 (1996).
46. Mukherjee, S. et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. 
European journal of pharmacology 505, 1–9, doi:10.1016/j.ejphar.2004.09.058 (2004).
47. Marini, P., Cascio, M. G., King, A., Pertwee, R. G. & Ross, R. A. Characterization of cannabinoid receptor ligands in tissues 
natively expressing cannabinoid CB2 receptors. Br J Pharmacol. 169, 887–899, doi:10.1111/bph.12191 (2013).
48. Navarrete, F., Perez-Ortiz, J. M. & Manzanares, J. Cannabinoid CB(2) receptor-mediated regulation of impulsive-like behaviour 
in DBA/2 mice. Br. J. Pharmacol. 165, 260–273, doi:10.1111/j.1476-5381.2011.01542.x (2012).
49. Burston, J. J. et al. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of 
the knee joint. PLoS One 8, e80440, doi:10.1371/journal.pone.0080440 (2013).
50. Xu, H. et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of 
autoimmune uveoretinitis. J. Leukoc. Biol. 82, 532–541, doi:10.1189/jlb.0307159 (2007).
51. Kimball, E. S., Palmer, J. M., D’Andrea, M. R., Hornby, P. J. & Wade, P. R. Acute colitis induction by oil of mustard results in 
later development of an IBS-like accelerated upper GI transit in mice. American journal of physiology. Gastrointestinal and liver 
physiology 288, G1266–1273, doi:10.1152/ajpgi.00444.2004 (2005).
52. Fujii, M. et al. Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway 
after subarachnoid hemorrhage in rats. Experimental neurology 261, 396–403, doi:10.1016/j.expneurol.2014.07.005 (2014).
53. Fraga-Silva, R. A. et al. Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction 
in hypercholesterolemic mice. Clinical & developmental immunology 2013, 263846, doi:10.1155/2013/263846 (2013).
54. Shao, B. Z. et al. Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via 
activation of autophagy and inhibiting NLRP3 inflammasome. CNS neuroscience & therapeutics 20, 1021–1028, doi:10.1111/
cns.12349 (2014).
55. Sardinha, J., Kelly, M. E., Zhou, J. & Lehmann, C. Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. 
Mediators of inflammation 2014, 978678, doi:10.1155/2014/978678 (2014).
56. Lehmann, C. et al. Cannabinoid receptor 2 activation reduces intestinal leukocyte recruitment and systemic inflammatory 
mediator release in acute experimental sepsis. Critical care 16, R47, doi:10.1186/cc11248 (2012).
57. Gui, H. et al. Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. 
Rheumatology 53, 802–809, doi:10.1093/rheumatology/ket447 (2014).
58. Davies, L. C., Jenkins, S. J., Allen, J. E. & Taylor, P. R. Tissue-resident macrophages. Nature immunology 14, 986–995, doi:10.1038/
ni.2705 (2013).
59. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428–435, doi:10.1038/nature07201 (2008).
Author Contributions
L.T. designed and performed experiments, prepared the figures and wrote the manuscript. I.C., T.K., 
M.H.B., A.B. and A.J.I. performed experiments and reviewed the manuscript. M.G.B. and A.R provided 
experimental reagents and reviewed the manuscript. DRG designed and performed experiments and 
reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Taylor, L. et al. Primary Macrophage Chemotaxis Induced by Cannabinoid 
Receptor 2 Agonists Occurs Independently of the CB 2 Receptor. Sci. Rep. 5, 10682; doi: 10.1038/
srep10682 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
